1,2,3,6-tetrahydro-4-phenyl-1-((3-phenyl-3-cyclohexen-1-yl)methyl)pyridine has been researched along with apomorphine in 2 studies
| Studies (1,2,3,6-tetrahydro-4-phenyl-1-((3-phenyl-3-cyclohexen-1-yl)methyl)pyridine) | Trials (1,2,3,6-tetrahydro-4-phenyl-1-((3-phenyl-3-cyclohexen-1-yl)methyl)pyridine) | Recent Studies (post-2010) (1,2,3,6-tetrahydro-4-phenyl-1-((3-phenyl-3-cyclohexen-1-yl)methyl)pyridine) | Studies (apomorphine) | Trials (apomorphine) | Recent Studies (post-2010) (apomorphine) |
|---|---|---|---|---|---|
| 14 | 1 | 0 | 9,205 | 287 | 780 |
| Protein | Taxonomy | 1,2,3,6-tetrahydro-4-phenyl-1-((3-phenyl-3-cyclohexen-1-yl)methyl)pyridine (IC50) | apomorphine (IC50) |
|---|---|---|---|
| Tryptophan 5-hydroxylase 1 | Rattus norvegicus (Norway rat) | 0.22 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0146 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 7.75 | |
| D | Rattus norvegicus (Norway rat) | 0.4744 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.1432 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.063 | |
| D(2) dopamine receptor | Bos taurus (cattle) | 0.3385 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.025 | |
| D(4) dopamine receptor | Homo sapiens (human) | 0.025 | |
| D(1B) dopamine receptor | Homo sapiens (human) | 0.025 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.063 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.063 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 7.75 | |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.1432 | |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.1432 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.025 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 7.75 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0813 | |
| E3 ubiquitin-protein ligase Mdm2 | Homo sapiens (human) | 0.205 | |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | 1.35 | |
| D | Bos taurus (cattle) | 0.3385 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caprathe, BW; Downing, DM; Glase, SA; Heffner, TG; Jaen, JC; Johnson, SJ; Kesten, SR; MacKenzie, RG; Meltzer, LT; Wright, JL | 1 |
| Christoffersen, CL; Corbin, AE; Heffner, TG; Meltzer, LT; Ninteman, FW; Serpa, KA; Wiley, JN; Wise, LD | 1 |
2 other study(ies) available for 1,2,3,6-tetrahydro-4-phenyl-1-((3-phenyl-3-cyclohexen-1-yl)methyl)pyridine and apomorphine
| Article | Year |
|---|---|
The discovery and structure-activity relationships of 1,2,3,6-tetrahydro-4-phenyl-1-[(arylcyclohexenyl)alkyl]pyridines. Dopamine autoreceptor agonists and potential antipsychotic agents.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Antipsychotic Agents; Avoidance Learning; Brain; CHO Cells; Cricetinae; Crystallography, X-Ray; Cyclic AMP; Cyclohexanes; Cyclohexenes; Dopamine; Dopamine Agonists; Mice; Models, Molecular; Molecular Structure; Motor Activity; Pyridines; Rats; Receptors, Dopamine; Saimiri; Stereoisomerism; Structure-Activity Relationship; Substantia Nigra | 1994 |
CI-1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antipsychotic Agents; Apomorphine; Autoreceptors; Avoidance Learning; Basal Ganglia Diseases; Dopamine Agonists; Male; Mice; Motor Activity; Rats; Rats, Sprague-Dawley; Saimiri | 1995 |